Chimerix, Inc. (CMRX)

Market Cap	801.08M
Revenue (ttm)	212,000
Net Income (ttm)	-88.39M
Shares Out	93.80M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	755,560
Open	8.52
Previous Close	8.55
Day's Range	8.54 - 8.55
52-Week Range	0.75 - 8.55
Beta	-0.18
Analysts	Hold
Price Target	8.51 (-0.35%)
Earnings Date	May 5, 2025

About CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 11, 2013
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: CMRX
• Website: https://www.chimerix.com

Financial Performance

In 2024, Chimerix's revenue was $212,000, a decrease of -34.57% compared to the previous year's $324,000. Losses were -$88.39 million, 7.66% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for CMRX stock is "Hold." The 12-month stock price target is $8.51, which is a decrease of -0.35% from the latest price.

Price Target

$8.51

(-0.35% downside)

Analyst Consensus: Hold